ASCO 2023 | An overview of the future of testicular cancer treatment

Ben Tran, MBBS, FACP, Peter MacCallum Cancer Centre, Melbourne, Australia, provides a horizon scan in the testicular cancer field. In patients who are cisplatin resistant, the intensification of treatment in first-line may increase the probability of cure and reduce the likelihood of future salvage chemotherapy. microRNA-371has been shown to be a marker of minimal residual disease (MRD) in stage one testes cancer. A post orchidectomy specimen was shown to detect over half the future recurrences via a plasma-based microRNA-371 assay. Prospective studies aim to confirm these findings. Additionally, a study is researching primary retroperitoneal lymph node dissection (PRLND) for stage II seminoma. This would remove the need for chemotherapy or radiotherapy. FDG-PET scans were implemented before surgery reduced the need for surgery in benign cases. Post surgery bleomycin, etoposide, and platinum (BEP) adjuvant chemotherapy reduced recurrences. A novel treatment for refractory testes cancer involves a claudin-6 (which is highly expressed in testes cancer) targeted CAR-T cell therapy that has shown promising results. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.